Low-Dose Eltrombopag in a Patient with Chronic Idiopathic Thrombocytopenic Purpura Post Sleeve Gastrectomy

Idiopathic thrombocytopenic purpura (ITP) is a disease in which the immune system attacks platelets and causes decrease in its number exposing the patient to risk of bleeding. It is diagnosed by exclusion. Eltrombopag is a thrombopoietin receptor agonist which is used as second-line treatment for patients with ITP. The usual starting dose is 25 mg daily and maintenance dose is 75 mg daily. Little is known about the dose of eltrombopag in patients with sleeve gastrectomy since reduction in the amount of functioning gastrointestinal tract after gastric bypass surgery leads to decreased time to drug absorption and reduced drug bioavailability. Here we are reporting a 46-year-old female with ITP and sleeve gastrectomy who responded to low-dose eltrombopag 25 mg every other day, which is equivalent to 12.5 mg daily, and maintained adequate platelet counts on this dose.

Download Full-text

CP-080 Thrombopoietin receptor agonist treatment in idiopathic thrombocytopenic purpura

European Journal of Hospital Pharmacy ◽

10.1136/ejhpharm-2015-000639.76 ◽

2015 ◽

Vol 22 (Suppl 1) ◽

pp. A32.1-A32

Author(s):

MH García Lagunar ◽

I Español Morales ◽

M Martínez Penella ◽

I Muñoz García ◽

M Gutiérrez Cívicos ◽

...

Keyword(s):

Idiopathic Thrombocytopenic Purpura ◽

Receptor Agonist ◽

Thrombocytopenic Purpura ◽

Thrombopoietin Receptor ◽

Thrombopoietin Receptor Agonist

Download Full-text

Neck dissection in a patient treated with refractory idiopathic thrombocytopenic purpura who received a thrombopoietin receptor agonist and γ-globulin preoperatively: a case report

Japanese Journal of Oral & Maxillofacial Surgery ◽

10.5794/jjoms.66.382 ◽

2020 ◽

Vol 66 (8) ◽

pp. 382-387

Author(s):

Miho UETA ◽

Kazuki TAKAOKA ◽

Michiyo NISHIDA ◽

Kyohei YOSHIKAWA ◽

Kazuma NOGUCHI ◽

...

Keyword(s):

Case Report ◽

Neck Dissection ◽

Idiopathic Thrombocytopenic Purpura ◽

Receptor Agonist ◽

Thrombocytopenic Purpura ◽

Thrombopoietin Receptor ◽

Thrombopoietin Receptor Agonist

Download Full-text

Eltrombopag: An Oral Thrombopoietin Receptor Agonist for the Treatment of Idiopathic Thrombocytopenic Purpura

Clinical Therapeutics ◽

10.1016/j.clinthera.2011.10.004 ◽

2011 ◽

Vol 33 (11) ◽

pp. 1560-1576 ◽

Cited By ~ 11

Author(s):

Yang Zhang ◽

Jill M. Kolesar

Keyword(s):

Idiopathic Thrombocytopenic Purpura ◽

Receptor Agonist ◽

Thrombocytopenic Purpura ◽

Thrombopoietin Receptor ◽

Thrombopoietin Receptor Agonist

Download Full-text

Review article: THE ROLE OF ELTROMBOPAG AND ROMIPLOSTIM AS THE THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): WHAT IS TPO-RA, WHEN TPO-RA IS USED AND HOW TO TAKE TPO-RA?

Folia Medica Indonesiana ◽

10.20473/fmi.v51i3.2840 ◽

2016 ◽

Vol 51 (3) ◽

pp. 203 ◽

Cited By ~ 1

Author(s):

Jefri Pratama Susanto

Keyword(s):

Idiopathic Thrombocytopenic Purpura ◽

Receptor Agonist ◽

Dose Adjustment ◽

Review Article ◽

Platelet Destruction ◽

Thrombocytopenic Purpura ◽

Platelet Production ◽

Thrombopoietin Receptor ◽

Thrombopoietin Receptor Agonist

Idiopathic thrombocytopenic purpura is a autoimmune disease characterized thrombocytopenia casued by excessive platelet destruction. However, both platelet destruction and reduced thrombopoietin level are occurred in some cases. Therefore, new management of ITP is emerged which target is to increase platelet production rate via eltrombopag or romiplostim as the thrombopoietin receptor agonist (TPO-RA). Eltrombopag is given orally while romiplostim is given subcutaneously or intravenously and dose adjustment is depend on platelet count. Both eltrombopag and romiplostim is indicated in minimal response glucocorticoid or intravenous immunoglobulin or splenetomy treatment.

Download Full-text